Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Zorifertinib in Chinese Patients with EGFRm+ NSCLC and CNS Metastases
NCT03360929Phase 2Completed
- Sponsor
- LYZZ Alpha Holding Ltd
- Start
- Oct 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zorifertinib in non-small cell lung cancer (NSCLC), sponsored by LYZZ Alpha Holding Ltd. Started Oct 2017; status: completed.
02
Drugs
zorifertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03360929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03360929.